- US-listed companies
- REGENEREX PHARMA, INC.
- Income statement
REGENEREX PHARMA, INC. (RGPX) Income statement
Market cap
P/E ratio
| 2011/11 | 2012/11 | 2014/11 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | - | - | - | - | - | 2,608 | 1,775 | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | - | |
| Cost of revenue | - | - | - | - | - | 1,712 | 246,692 | - | - | - | - |
| Gross profit | - | - | - | - | - | 896 | -244,917 | - | - | - | - |
| Gross margin (%) | - | - | - | - | - | - | - | - | - | ||
| Research & development | - | - | - | - | - | - | - | - | - | 2 | 662,479 |
| Selling, general & administrative | - | - | - | - | - | - | - | - | - | - | 1 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | ||
| Operating expenses | - | - | - | 49,451 | -91,734 | 77,899 | 61,314 | 126,267 | 96,171 | 3 | 2 |
| Operating income | - | - | - | -49,451 | -91,734 | -77,003 | -306,231 | -126,267 | -96,171 | -3,465,825 | -1,826,097 |
| Income before tax | - | - | -467,756 | - | - | - | - | - | - | - | - |
| Provision for income taxes | - | - | - | - | - | - | - | - | - | - | -2,717 |
| Net income | -212,146 | -659,736 | 859,827 | 49,671 | 93,579 | 111,589 | 353,752 | -195,591 | -137,330 | -3,543,827 | -2,527,041 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - |